Published in J Clin Microbiol on October 01, 2005
The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev (2010) 4.22
Diversity of cultivated endophytic bacteria from sugarcane: genetic and biochemical characterization of Burkholderia cepacia complex isolates. Appl Environ Microbiol (2007) 1.38
Multilocus sequence typing breathes life into a microbial metagenome. PLoS One (2006) 1.23
The mgtC gene of Burkholderia cenocepacia is required for growth under magnesium limitation conditions and intracellular survival in macrophages. Infect Immun (2006) 1.22
Variation of the antimicrobial susceptibility profiles of Burkholderia cepacia complex clonal isolates obtained from chronically infected cystic fibrosis patients: a five-year survey in the major Portuguese treatment center. Eur J Clin Microbiol Infect Dis (2008) 1.12
Exceptionally high representation of Burkholderia cepacia among B. cepacia complex isolates recovered from the major Portuguese cystic fibrosis center. J Clin Microbiol (2007) 0.96
Genetic diversity of Burkholderia contaminans isolates from cystic fibrosis patients in Argentina. J Clin Microbiol (2012) 0.91
Structure of Burkholderia cepacia UDP-glucose dehydrogenase (UGD) BceC and role of Tyr10 in final hydrolysis of UGD thioester intermediate. J Bacteriol (2011) 0.89
Clinical and environmental Burkholderia strains: biofilm production and intracellular survival. Curr Microbiol (2007) 0.86
SNaPBceBcon: a Practical Tool for Identification and Genotyping of Burkholderia cepacia and Burkholderia contaminans. J Clin Microbiol (2015) 0.78
Unusual distribution of Burkholderia cepacia complex species in Danish cystic fibrosis clinics may stem from restricted transmission between patients. J Clin Microbiol (2010) 0.78
Development of a multiple-locus variable-number tandem-repeat typing scheme for genetic fingerprinting of Burkholderia cenocepacia and application to nationwide epidemiological analysis. J Clin Microbiol (2014) 0.75
Complete Genome Sequence of Burkholderia cenocepacia CR318, a Phosphate-Solubilizing Bacterium Isolated from Corn Root. Genome Announc (2017) 0.75
Burkholderia cepacia complex in cystic fibrosis in a Brazilian reference center. Med Microbiol Immunol (2017) 0.75
Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol (1995) 88.05
Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev (1996) 13.91
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet (1993) 7.12
Principles and applications of methods for DNA-based typing of microbial organisms. J Clin Microbiol (1999) 5.88
Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol (1997) 5.60
DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol (2000) 4.71
Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet (1990) 4.39
Typing of Staphylococcus aureus by pulsed-field gel electrophoresis, zymotyping, capsular typing, and phage typing: resolution of clonal relationships. J Clin Microbiol (1993) 4.36
Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol (2001) 4.12
Burkholderia cepacia: medical, taxonomic and ecological issues. J Med Microbiol (1996) 4.11
Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol (2001) 4.02
Specific genomic fingerprints of phytopathogenic Xanthomonas and Pseudomonas pathovars and strains generated with repetitive sequences and PCR. Appl Environ Microbiol (1994) 3.80
Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol (2002) 3.44
The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med (1995) 3.36
Burkholderia cepacia. Management issues and new insights. Clin Chest Med (1998) 3.23
Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J Clin Microbiol (1999) 2.87
Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol (1994) 2.74
Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol (2000) 2.63
Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med (2001) 2.55
Burkholderia cenocepacia sp. nov.--a new twist to an old story. Res Microbiol (2003) 2.49
Infection control in cystic fibrosis. Clin Microbiol Rev (2004) 2.45
Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest (2000) 2.41
Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr (2001) 2.31
Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol (2001) 2.27
Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis (2002) 2.26
Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol (2005) 2.18
Differential subsequence conservation of interspersed repetitive Streptococcus pneumoniae BOX elements in diverse bacteria. Genome Res (1995) 1.92
An epidemic Burkholderia cepacia complex strain identified in soil. Lancet (2002) 1.88
Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. Curr Opin Pulm Med (1998) 1.86
Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol (1995) 1.79
Comparative assessment of genotyping methods for epidemiologic study of Burkholderia cepacia genomovar III. J Clin Microbiol (2002) 1.79
Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax (1995) 1.78
Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med (2001) 1.69
Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol (1999) 1.64
Type characterisation and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol (1996) 1.60
Proposal to accommodate Burkholderia cepacia genomovar VI as Burkholderia dolosa sp. nov. Int J Syst Evol Microbiol (2004) 1.58
Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status. J Clin Microbiol (2001) 1.50
Burkholderia cepacia complex bacteria from clinical and environmental sources in Italy: genomovar status and distribution of traits related to virulence and transmissibility. J Clin Microbiol (2002) 1.48
Polyclonal outbreak of Burkholderia cepacia complex bacteraemia in haemodialysis patients. J Hosp Infect (2003) 1.47
Evidence of transmission of Burkholderia cepacia, Burkholderia multivorans and Burkholderia dolosa among persons with cystic fibrosis. FEMS Microbiol Lett (2003) 1.38
Molecular analysis of Burkholderia cepacia complex isolates from a Portuguese cystic fibrosis center: a 7-year study. J Clin Microbiol (2003) 1.37
Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer Camp Study Group. J Pediatr (1994) 1.36
Inapparent transmission of Pseudomonas (Burkholderia) cepacia among patients with cystic fibrosis. Pediatr Infect Dis J (1994) 1.34
Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax (2004) 1.32
Distribution of genes encoding putative transmissibility factors among epidemic and nonepidemic strains of Burkholderia cepacia from cystic fibrosis patients in the United Kingdom. J Clin Microbiol (2000) 1.24
Molecular epidemiology of Burkholderia species. Front Biosci (2003) 1.16
Population structure analysis of Burkholderia cepacia genomovar III: varying degrees of genetic recombination characterize major clonal complexes. Microbiology (2003) 1.12
Six-year molecular analysis of Burkholderia cepacia complex isolates among cystic fibrosis patients at a referral center for lung transplantation. J Clin Microbiol (2002) 1.06
Molecular characterization of Burkholderia cepacia isolates from cystic fibrosis (CF) patients in an Italian CF center. Res Microbiol (2003) 1.02
Species distribution and ribotype diversity of Burkholderia cepacia complex isolates from French patients with cystic fibrosis. J Clin Microbiol (2004) 1.01
Genomovar diversity amongst Burkholderia cepacia complex isolates from an Australian adult cystic fibrosis unit. Eur J Clin Microbiol Infect Dis (2003) 1.00
Transmission and prevalence of Burkholderia cepacia in Welsh cystic fibrosis patients. Respir Med (1998) 0.98
Diversity of transconjugants that acquired plasmid pJP4 or pEMT1 after inoculation of a donor strain in the A- and B-horizon of an agricultural soil and description of Burkholderia hospita sp. nov. and Burkholderia terricola sp. nov. Syst Appl Microbiol (2002) 0.96
Epidemiology and clinical course of Burkholderia cepacia complex infections, particularly those caused by different Burkholderia cenocepacia strains, among patients attending an Italian Cystic Fibrosis Center. J Clin Microbiol (2004) 0.96
Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients. Eur Respir J (2004) 0.96
Microbiologic data overview of Italian cystic fibrosis patients. Eur J Epidemiol (1997) 0.94
European-wide distribution of Pseudomonas aeruginosa clone C. Clin Microbiol Infect (2003) 0.93
Identification by subtractive hybridization of a novel insertion element specific for two widespread Burkholderia cepacia genomovar III strains. J Clin Microbiol (2003) 0.93
Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation. Thorax (2004) 0.90
Genomovar distribution of the Burkholderia cepacia complex differs significantly between Czech and Slovak patients with cystic fibrosis. J Med Microbiol (2003) 0.90
Molecular comparison of isolates of Burkholderia multivorans from patients with cystic fibrosis in the United Kingdom. J Clin Microbiol (2003) 0.85
[Prevention and control of respiratory tract infections in the network of Italian Centers for Cystic Fibrosis]. Assist Inferm Ric (2004) 0.76
Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet (1993) 7.12
Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol (1997) 5.60
DNA-Based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol (2000) 4.71
Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A (2008) 4.60
Burkholderia cepacia: medical, taxonomic and ecological issues. J Med Microbiol (1996) 4.11
Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol (2001) 4.02
Diagnostically and experimentally useful panel of strains from the Burkholderia cepacia complex. J Clin Microbiol (2000) 3.77
Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax (2004) 3.25
Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet (2001) 3.24
Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol (1999) 3.19
Characterization of some Actinomyces-like isolates from human clinical specimens: reclassification of Actinomyces suis (Soltys and Spratling) as Actinobaculum suis comb. nov. and description of Actinobaculum schaalii sp. nov. Int J Syst Bacteriol (1997) 2.95
Identification and population structure of Burkholderia stabilis sp. nov. (formerly Burkholderia cepacia genomovar IV). J Clin Microbiol (2000) 2.63
Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. Science (1997) 2.56
Cancer stem cells--old concepts, new insights. Cell Death Differ (2008) 2.56
Classification of Alcaligenes faecalis-like isolates from the environment and human clinical samples as Ralstonia gilardii sp. nov. Int J Syst Bacteriol (1999) 2.52
Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest (2000) 2.41
Burkholderia ambifaria sp. nov., a novel member of the Burkholderia cepacia complex including biocontrol and cystic fibrosis-related isolates. Int J Syst Evol Microbiol (2001) 2.27
Pseudomonas cepacia in inpatients with cystic fibrosis. Lancet (1991) 2.27
Riemerella anatipestifer gen. nov., comb. nov., the causative agent of septicemia anserum exsudativa, and its phylogenetic affiliation within the Flavobacterium-Cytophaga rRNA homology group. Int J Syst Bacteriol (1993) 2.24
Description of Pandoraea gen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensis comb. nov. Int J Syst Evol Microbiol (2000) 2.20
Arcobacter species in humans. Emerg Infect Dis (2004) 2.11
Identification of Pandoraea species by 16S ribosomal DNA-based PCR assays. J Clin Microbiol (2001) 2.09
Comparison of the MB/BacT and BACTEC 460 TB systems for recovery of mycobacteria from various clinical specimens. J Clin Microbiol (1999) 2.09
Presence of vancomycin-resistant enterococci in farm and pet animals. Antimicrob Agents Chemother (1996) 2.06
Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex. J Clin Microbiol (2001) 2.06
Vancomycin-resistant enterococci colonizing the intestinal tracts of hospitalized patients. J Clin Microbiol (1995) 2.04
Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis (2001) 2.04
Development of a multiplex PCR assay for the simultaneous detection and identification of Arcobacter butzleri, Arcobacter cryaerophilus and Arcobacter skirrowii. FEMS Microbiol Lett (2000) 2.01
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer (2010) 1.99
Ralstonia taiwanensis sp. nov., isolated from root nodules of Mimosa species and sputum of a cystic fibrosis patient. Int J Syst Evol Microbiol (2001) 1.98
Classification of metal-resistant bacteria from industrial biotopes as Ralstonia campinensis sp. nov., Ralstonia metallidurans sp. nov. and Ralstonia basilensis Steinle et al. 1998 emend. Int J Syst Evol Microbiol (2001) 1.94
Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer (2006) 1.91
Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother (2000) 1.87
Triple negative breast cancers: clinical and prognostic implications. Eur J Cancer (2009) 1.83
Fatal pulmonary infection due to multidrug-resistant Mycobacterium abscessus in a patient with cystic fibrosis. J Clin Microbiol (2001) 1.83
Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture. J Clin Microbiol (2000) 1.82
Burkholderia cepacia and cystic fibrosis: do natural environments present a potential hazard? J Clin Microbiol (1995) 1.79
Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ (2008) 1.76
Increased cardiomyocyte apoptosis and changes in proapoptotic and antiapoptotic genes bax and bcl-2 during left ventricular adaptations to chronic pressure overload in the rat. Circulation (1999) 1.75
Burkholderia fungorum sp. nov. and Burkholderia caledonica sp. nov., two new species isolated from the environment, animals and human clinical samples. Int J Syst Evol Microbiol (2001) 1.73
Classification of Ralstonia pickettii biovar 3/'thomasii' strains (Pickett 1994) and of new isolates related to nosocomial recurrent meningitis as Ralstonia mannitolytica sp. nov. Int J Syst Evol Microbiol (2001) 1.67
Burkholderia phytofirmans sp. nov., a novel plant-associated bacterium with plant-beneficial properties. Int J Syst Evol Microbiol (2005) 1.66
Assignment of Centers for Disease Control group IVc-2 to the genus Ralstonia as Ralstonia paucula sp. nov. Int J Syst Bacteriol (1999) 1.64
Bacteremia caused by a novel Bordetella species, "B. hinzii". J Clin Microbiol (1994) 1.63
Antimicrobial susceptibilities of Campylobacter strains isolated from food animals in Belgium. J Antimicrob Chemother (2001) 1.62
Clinical spectrum of infections due to the newly described Actinomyces species A. turicensis, A. radingae, and A. europaeus. J Clin Microbiol (1999) 1.61
Burkholderia cepacia genomovar VI, a new member of the Burkholderia cepacia complex isolated from cystic fibrosis patients. Int J Syst Evol Microbiol (2001) 1.61
Characteristics of Bordetella hinzii strains isolated from a cystic fibrosis patient over a 3-year period. J Clin Microbiol (1996) 1.58
In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol (2010) 1.58
Isolation measures for prevention of infection with respiratory pathogens in cystic fibrosis: a systematic review. J Hosp Infect (2006) 1.57
Synthesis of multiple N-acylhomoserine lactones is wide-spread among the members of the Burkholderia cepacia complex. Syst Appl Microbiol (2001) 1.54
Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. Blood (1999) 1.54
Identification of Burkholderia species and genomovars from cystic fibrosis patients by AFLP fingerprinting. Int J Syst Bacteriol (1999) 1.53
Evaluation of arbitrarily primed PCR analysis and pulsed-field gel electrophoresis of large genomic DNA fragments for identification of enterococci important in human medicine. Int J Syst Bacteriol (1997) 1.50
Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology, and genomovar status. J Clin Microbiol (2001) 1.50
Polyclonal outbreak of Burkholderia cepacia complex bacteraemia in haemodialysis patients. J Hosp Infect (2003) 1.47
Whole-genome organization and functional properties of miniature DNA insertion sequences conserved in pathogenic Neisseriae. Gene (2001) 1.47
Hypermutation in pathogenic bacteria: frequent phase variation in meningococci is a phenotypic trait of a specialized mutator biotype. Mol Cell (1999) 1.45
A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg (2008) 1.40
Evaluation of the discriminatory power of typing methods for Neisseria gonorrhoeae. J Clin Microbiol (1999) 1.39
Burkholderia cepacia genomovar III Is a common plant-associated bacterium. Appl Environ Microbiol (2001) 1.39
Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals. Clin Microbiol Infect (2011) 1.39
Group A streptococcal genotypes from pediatric throat isolates in Rome, Italy. J Clin Microbiol (2001) 1.38
Differentiation between Streptococcus gallolyticus strains of human clinical and veterinary origins and Streptococcus bovis strains from the intestinal tracts of ruminants. J Clin Microbiol (1998) 1.34
Is "Campylobacter upsaliensis" an unrecognised cause of human diarrhoea? Lancet (1990) 1.32
Recovery of Burkholderia cenocepacia strain PHDC from cystic fibrosis patients in Europe. Thorax (2004) 1.32
Heart-targeted overexpression of caspase3 in mice increases infarct size and depresses cardiac function. Proc Natl Acad Sci U S A (2001) 1.31
Specific detection of Campylobacter concisus by PCR amplification of 23S rDNA areas. Mol Cell Probes (1995) 1.29
'Candidatus Helicobacter suis', a gastric helicobacter from pigs, and its phylogenetic relatedness to other gastrospirilla. Int J Syst Bacteriol (1999) 1.28
Identification of aesculin-hydrolyzing streptococci, lactococci, aerococci and enterococci from subclinical intramammary infections in dairy cows. Vet Microbiol (1999) 1.25
Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer (2009) 1.23
Neisseria weaveri sp. nov. (formerly CDC group M-5), from dog bite wounds of humans. Int J Syst Bacteriol (1993) 1.22
Development of a new protocol for the isolation and quantification of Arcobacter species from poultry products. Int J Food Microbiol (2001) 1.21
Comparison of glycopeptide-resistant Enterococcus faecium isolates and glycopeptide resistance genes of human and animal origins. Antimicrob Agents Chemother (1999) 1.21
Investigation of an outbreak of Campylobacter upsaliensis in day care centers in Brussels: analysis of relationships among isolates by phenotypic and genotypic typing methods. J Infect Dis (1995) 1.21
Acidovorax, a new genus for Pseudomonas facilis, Pseudomonas delafieldii, E. Falsen (EF) group 13, EF group 16, and several clinical isolates, with the species Acidovorax facilis comb. nov., Acidovorax delafieldii comb. nov., and Acidovorax temperans sp. nov. Int J Syst Bacteriol (1990) 1.21
Comparison of isolation media for recovery of Burkholderia cepacia complex from respiratory secretions of patients with cystic fibrosis. J Clin Microbiol (1999) 1.21
Burkholderia (Pseudomonas) cepacia and cystic fibrosis: the epidemiology in Belgium. Acta Clin Belg (1996) 1.20
Identification of clinically relevant viridans streptococci by analysis of transfer DNA intergenic spacer length polymorphism. Int J Syst Bacteriol (1999) 1.20
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J (2002) 1.20
Genotypic diversity of Campylobacter lari isolated from mussels and oysters in The Netherlands. Int J Food Microbiol (1997) 1.19
Burkholderia cepacia complex: distribution of genomovars among isolates from the maize rhizosphere in Italy. Environ Microbiol (2001) 1.18
Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer. Br J Cancer (2012) 1.15
Isolation of Campylobacter concisus from feces of children with and without diarrhea. J Clin Microbiol (1996) 1.15
A cultured strain of "Helicobacter heilmannii," a human gastric pathogen, identified as H. bizzozeronii: evidence for zoonotic potential of Helicobacter. Emerg Infect Dis (2001) 1.14
Hypovitaminosis-C and Pulmonary Tuberculosis. Br Med J (1940) 1.14
PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. Br J Cancer (2012) 1.13
Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy. Histopathology (2007) 1.13
Molecular discrimination between Campylobacter jejuni, Campylobacter coli, Campylobacter lari and Campylobacter upsaliensis by polymerase chain reaction based on a novel putative GTPase gene. Mol Cell Probes (1997) 1.13